Financiere de Tubize (CHIX:TUBB) Tariff Resilience Score: 0/10 (As of Jul. 08, 2026)


CHIX:TUBB Financiere de Tubize SA CHIX:TUBB
44 GF Score
Price €235.20
! 2 Warning Signs
View Full Analysis

What is Financiere de Tubize Tariff Resilience Score?

Financiere de Tubize has the Tariff Resilience Score of 0, which implies that the company might have .

Financiere de Tubize has

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Financiere de Tubize might have .

Financiere de Tubize  (CHIX:TUBb) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Financiere de Tubize Tariff Resilience Score Related Terms

CHIX:TUBB
44GF Score
Financiere de Tubize SA CHIX:TUBB
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Financiere de Tubize Business Description

Address Allee de la Recherche, 60, Brussels, BEL, 1070
Financiere de Tubize SA is a holding company that owns a stake in UCB, a biopharmaceutical company. UCB is a world-wide biotechnology company that develops treatments for conditions related to neurology and immunology. UCB generates the vast majority of its revenue in the United States, followed by Europe and other international markets. Majority of its sales revenue is derived from its neurology products, followed by its immunology products. The company's plan focuses on leveraging scientific advances and skills in areas such as genetics, biomarkers, and human biology.
44GF Score

Get the complete analysis for CHIX:TUBB

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€235.20
Price